Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Nature ; 604(7905): 343-348, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-35322228

RESUMO

Gene therapy is a potentially curative medicine for many currently untreatable diseases, and recombinant adeno-associated virus (rAAV) is the most successful gene delivery vehicle for in vivo applications1-3. However, rAAV-based gene therapy suffers from several limitations, such as constrained DNA cargo size and toxicities caused by non-physiological expression of a transgene4-6. Here we show that rAAV delivery of a suppressor tRNA (rAAV.sup-tRNA) safely and efficiently rescued a genetic disease in a mouse model carrying a nonsense mutation, and effects lasted for more than 6 months after a single treatment. Mechanistically, this was achieved through a synergistic effect of premature stop codon readthrough and inhibition of nonsense-mediated mRNA decay. rAAV.sup-tRNA had a limited effect on global readthrough at normal stop codons and did not perturb endogenous tRNA homeostasis, as determined by ribosome profiling and tRNA sequencing, respectively. By optimizing the AAV capsid and the route of administration, therapeutic efficacy in various target tissues was achieved, including liver, heart, skeletal muscle and brain. This study demonstrates the feasibility of developing a toolbox of AAV-delivered nonsense suppressor tRNAs operating on premature termination codons (AAV-NoSTOP) to rescue pathogenic nonsense mutations and restore gene function under endogenous regulation. As nonsense mutations account for 11% of pathogenic mutations, AAV-NoSTOP can benefit a large number of patients. AAV-NoSTOP obviates the need to deliver a full-length protein-coding gene that may exceed the rAAV packaging limit, elicit adverse immune responses or cause transgene-related toxicities. It therefore represents a valuable addition to gene therapeutics.


Assuntos
Códon sem Sentido , Dependovirus , Terapia Genética , Adenoviridae , Animais , Códon sem Sentido/genética , Códon de Terminação/genética , Códon de Terminação/metabolismo , Dependovirus/genética , Doenças Genéticas Inatas/terapia , Vetores Genéticos , Humanos , Camundongos , Degradação do RNAm Mediada por Códon sem Sentido/genética , RNA de Transferência/genética , RNA de Transferência/metabolismo
2.
Adv Sci (Weinh) ; 6(21): 1900440, 2019 Nov 06.
Artigo em Inglês | MEDLINE | ID: mdl-31728271

RESUMO

Delivery of genome editing tools to mammalian zygotes has revolutionized animal modeling. However, the mechanical delivery method to introduce genes and proteins to zygotes remains a challenge for some animal species that are important in biomedical research. Here, an approach to achieve gene delivery and genome editing in nonhuman primate embryos is presented by infecting zygotes with recombinant adeno-associated viruses (rAAVs). Together with previous reports from the authors of this paper and others, this approach is potentially applicable to a broad range of mammals. In addition to genome editing and animal modeling, this rAAV-based method can facilitate gene function studies in early-stage embryos.

3.
Nat Biotechnol ; 36(9): 839-842, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-30102296

RESUMO

We report a genome-editing strategy to correct compound heterozygous mutations, a common genotype in patients with recessive genetic disorders. Adeno-associated viral vector delivery of Cas9 and guide RNA induces allelic exchange and rescues the disease phenotype in mouse models of hereditary tyrosinemia type I and mucopolysaccharidosis type I. This approach recombines non-mutated genetic information present in two heterozygous alleles into one functional allele without using donor DNA templates.


Assuntos
Alelos , Proteína 9 Associada à CRISPR , Genes Recessivos , Heterozigoto , Mutação , Animais , Dependovirus/genética , Edição de Genes , Vetores Genéticos , Camundongos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...